The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsClinical features and neuroimaging of PARK7-linked parkinsonismIn vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55Religiosity in patients with Parkinson's disease.Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.Manganese-induced parkinsonism and Parkinson's disease.[(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites.Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.The L-dopa response in vascular parkinsonism.Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.Chronic exposure to manganese alters brain responses to amphetamine: a pharmacological magnetic resonance imaging studyApplications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders.Parkinson's disease as a disconnection syndromeThe AS/AGU rat: a spontaneous model of disruption and degeneration in the nigrostriatal dopaminergic system.Extrastriatal dopaminergic circuits of the Basal Ganglia.Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's diseaseMonoamine reuptake inhibitors in Parkinson's disease.Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.Dopamine transporter: basic aspects and neuroimaging.Neurorestoration.Diagnostic considerations in juvenile parkinsonism.T1rho and T2rho MRI in the evaluation of Parkinson's disease.Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease.Relation of 18-F-Dopa PET with hypokinesia-rigidity, tremor and freezing in Parkinson's diseaseSingle photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders.[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.Role of a lateralized parietal-basal ganglia circuit in hierarchical pattern perception: evidence from Parkinson's disease.CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's diseasePatterns of prefrontal dysfunction in alcoholics with and without Korsakoff's syndrome, patients with Parkinson's disease, and patients with rupture and repair of the anterior communicating artery.Etiopathogenesis of Parkinson disease: a new beginning?Overview of radiopharmaceuticals for diagnosis of central nervous disorders.DIMETER: a haptic master device for tremor diagnosis in neurodegenerative diseases.Positron emission tomography neuroimaging in Parkinson's disease.Positron emission tomography imaging in neurological disorders.Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker.
P2860
Q21129423-0F72092F-6FF1-4259-A02F-7A97D77F772FQ28180436-3DF109F0-B529-488C-BB2B-FF411FB078A8Q28246922-A7C223D8-0B8D-4972-9940-42CA0D65CA8EQ30376722-56E94458-54D5-43CE-B42C-608F7E705F6AQ30671310-AFFE6154-2917-4541-B7B9-BC091CA4C682Q30924521-8C4932E0-0C0B-4718-B59E-AF7A1EEAB821Q31911300-BFB64F69-7B8C-456C-8F55-66DF9A55FE9BQ31949006-5F33DF7E-E768-4B5F-B929-3628F3F5F4E4Q32052220-F3EF070A-AA88-4011-B65E-151329EE138FQ33199702-1A8116B3-2330-40B4-B2E7-0F2805D08F2CQ33732447-6398FCEE-0598-4A6E-92C7-3F6F5FB3072FQ33733368-B21809A9-6C37-47B9-80DD-5B4F98FBC0C0Q33894434-65ABF082-BC1C-4078-B3A5-3FE9041FED9AQ33901047-1282AF08-2837-46C1-8E2D-F1DDD070A2B9Q33989384-275714C6-2A22-4349-806B-0E6581BA80F4Q34330022-EB72A95B-72A3-4E76-B831-602D13108BAFQ34414151-8E914FF9-A36C-4659-9129-29BF32CB6982Q34468544-D18EE9A0-010D-4BBD-8EBB-7BE8EFAC62F9Q34682391-A306047E-300B-44A6-9A88-9406A5AC1DA7Q35165280-C20B7B9F-AF00-4563-8C65-402A4A7146D7Q35454622-348A269B-73B6-4486-9910-A42C487DE2FCQ35552926-3E30CACD-DD7C-4025-B0A7-FED718CF744FQ35631869-CED1874E-59B1-44CD-95C4-CC23DF05F331Q35673290-9E94EC51-94F7-4393-B625-2EDBF2A9FB52Q35750201-A081B632-148F-4D84-A7BA-5B150313212BQ36326475-97349875-CD5C-403F-953A-49E80B71687BQ36528003-ABF06EE2-4D49-4E07-B6C0-9680B3ECE8DFQ36736517-E6DA8D01-0643-488B-B526-414AC5D8CC9FQ36743706-A36A3E12-D98F-483B-8212-A12EE88C1A85Q36901896-B09A1034-69A2-4090-A1DD-262F0729EF86Q37102910-82DD1475-F81F-490B-B9B3-7E69A81921C7Q37121244-E90C1898-C461-4FA5-A3EF-024ED5955D63Q37121555-8CE8F31E-623D-42C0-A6E9-7681D15BFB73Q37165733-5615EA98-8A63-4474-9196-B49E66D7EBC7Q37325334-AED4C557-B47C-4B5C-AF31-A9E4593197CDQ37420841-2C043458-4476-49F2-B5A6-916707442937Q37731026-5D57CAF7-F89A-471A-B4F3-465BA90248D1Q37929598-81771865-3446-4263-85A0-B86A50D4E6EAQ37980609-FAE9F979-FD4D-44BB-BAE0-A64D1F95C151Q38174524-3D0EAA01-1542-45DE-BEAD-91003BFFB058
P2860
The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
The nigrostriatal dopaminergic ...... ents with Parkinson's disease.
@en
The nigrostriatal dopaminergic ...... ents with Parkinson's disease.
@nl
type
label
The nigrostriatal dopaminergic ...... ents with Parkinson's disease.
@en
The nigrostriatal dopaminergic ...... ents with Parkinson's disease.
@nl
prefLabel
The nigrostriatal dopaminergic ...... ents with Parkinson's disease.
@en
The nigrostriatal dopaminergic ...... ents with Parkinson's disease.
@nl
P2093
P50
P921
P1433
P1476
The nigrostriatal dopaminergic ...... ents with Parkinson's disease.
@en
P2093
P304
P356
10.1001/ARCHNEUR.1990.00530120034007
P577
1990-12-01T00:00:00Z